NASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis $4.24 +0.08 (+1.92%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.24 0.00 (0.00%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Foghorn Therapeutics Stock (NASDAQ:FHTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Foghorn Therapeutics alerts:Sign Up Key Stats Today's Range$4.08▼$4.3450-Day Range$3.15▼$5.0152-Week Range$2.94▼$10.25Volume108,884 shsAverage Volume139,367 shsMarket Capitalization$235.79 millionP/E RatioN/ADividend YieldN/APrice Target$12.13Consensus RatingBuy Company OverviewFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Foghorn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreFHTX MarketRank™: Foghorn Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 488th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFoghorn Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFoghorn Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Foghorn Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Foghorn Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Foghorn Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.84% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Foghorn Therapeutics has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.84% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Foghorn Therapeutics has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.21 News SentimentFoghorn Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Foghorn Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for FHTX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.07% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Foghorn Therapeutics' insider trading history. Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FHTX Stock News HeadlinesFoghorn Therapeutics' (FHTX) Buy Rating Reiterated at HC WainwrightMay 3 at 3:11 AM | americanbankingnews.comFoghorn Therapeutics expands board with biotech veteransMay 3 at 12:27 AM | investing.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.May 4, 2025 | Stansberry Research (Ad)JMP Securities Reaffirms Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX)May 2 at 3:21 AM | americanbankingnews.comFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsMay 1 at 7:00 AM | globenewswire.comFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateApril 28, 2025 | globenewswire.comNature's Sunshine Products (NASDAQ:NATR) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head AnalysisApril 27, 2025 | americanbankingnews.comFoghorn Therapeutics (NASDAQ:FHTX) Now Covered by JMP SecuritiesApril 26, 2025 | americanbankingnews.comSee More Headlines FHTX Stock Analysis - Frequently Asked Questions How have FHTX shares performed this year? Foghorn Therapeutics' stock was trading at $4.72 on January 1st, 2025. Since then, FHTX stock has decreased by 10.2% and is now trading at $4.24. View the best growth stocks for 2025 here. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) released its quarterly earnings results on Thursday, March, 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.13. The company had revenue of $2.86 million for the quarter, compared to analyst estimates of $8.56 million. When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an IPO on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Foghorn Therapeutics' major shareholders? Top institutional investors of Foghorn Therapeutics include Exchange Traded Concepts LLC (0.05%). Insiders that own company stock include Samuel Agresta and Carlos Costa. View institutional ownership trends. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Foghorn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG). Company Calendar Last Earnings3/06/2025Today5/03/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FHTX CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$12.13 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+186.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,430,000.00 Net Margins-357.53% Pretax Margin-349.74% Return on EquityN/A Return on Assets-30.98% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.77 Sales & Book Value Annual Sales$22.60 million Price / Sales10.43 Cash FlowN/A Price / Cash FlowN/A Book Value($1.83) per share Price / Book-2.32Miscellaneous Outstanding Shares55,612,000Free Float50,568,000Market Cap$235.79 million OptionableOptionable Beta3.16 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:FHTX) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.